Correlation of rpoB Mutations with Minimal Inhibitory Concentration of Rifampin and Rifabutin in Mycobacterium tuberculosis in an HIV/AIDS Endemic Setting, South Africa
- PMID: 27994580
- PMCID: PMC5136537
- DOI: 10.3389/fmicb.2016.01947
Correlation of rpoB Mutations with Minimal Inhibitory Concentration of Rifampin and Rifabutin in Mycobacterium tuberculosis in an HIV/AIDS Endemic Setting, South Africa
Abstract
Treatment of tuberculosis (TB) and HIV co-infections is often complicated by drug-to-drug interactions between anti-mycobacterial and anti-retroviral agents. Rifabutin (RFB) is an alternative to rifampin (RIF) for TB regimens and is recommended for HIV patients concurrently receiving protease inhibitors because of reduced induction of CYP3A4. This study sought to determine the proportion of RFB susceptible isolates among RIF-resistant strains in a high HIV prevalence setting in South Africa. In addition, the study explored the association between rpoB mutations and minimum inhibitory concentrations (MIC) of RIF and RFB. A total of 189 multidrug resistant (MDR) Mycobacterium tuberculosis isolates from the Centre for Tuberculosis repository were analyzed. The MICs were determined using a MYCOTB Sensititre plate method and the rpoB gene was sequenced. Of the 189 MDR isolates, 138 (73%) showed resistance to both RIF and RFB, while 51 (27%) isolates were resistant to RIF but retained susceptibility to RFB. The S531L was the most frequent rpoB point mutation in 105/189 (56%) isolates, followed by H526Y in 27/189 (14%) isolates. Resistance to both RIF and RFB was found predominantly in association with mutations S531L (91/105, 87%), H526Y (20/27, 74%), and H526D (15/19, 79%), while D516V (15/17, 88%), and L533P (3/4, 75%) were found in RIF-resistant, RFB-susceptible isolates. This study has shown that up to 27% of MDR-TB patients in South Africa may benefit from a treatment regimen that includes RFB.
Keywords: HIV/AIDS; Mycobacterium tuberculosis; South Africa; minimum inhibitory concentration; point mutation; rifabutin; rifampicin; rpoB.
Figures
Similar articles
-
The beginning of the rpoB gene in addition to the rifampin resistance determination region might be needed for identifying rifampin/rifabutin cross-resistance in multidrug-resistant Mycobacterium tuberculosis isolates from Southern China.J Clin Microbiol. 2012 Jan;50(1):81-5. doi: 10.1128/JCM.05092-11. Epub 2011 Nov 9. J Clin Microbiol. 2012. PMID: 22075601 Free PMC article.
-
Profiling of rpoB mutations and MICs for rifampin and rifabutin in Mycobacterium tuberculosis.J Clin Microbiol. 2014 Jun;52(6):2157-62. doi: 10.1128/JCM.00691-14. Epub 2014 Apr 16. J Clin Microbiol. 2014. PMID: 24740074 Free PMC article.
-
Rifampin-resistance-associated mutations in the rifampin-resistance-determining region of the rpoB gene of Mycobacterium tuberculosis clinical isolates in Shanghai, PR China.J Med Microbiol. 2021 Mar;70(3). doi: 10.1099/jmm.0.001317. Epub 2021 Jan 28. J Med Microbiol. 2021. PMID: 33507146
-
Association between the rifampicin resistance mutations and rifabutin susceptibility in Mycobacterium tuberculosis: A meta-analysis.J Glob Antimicrob Resist. 2025 Jan;40:53-61. doi: 10.1016/j.jgar.2024.11.014. Epub 2024 Nov 29. J Glob Antimicrob Resist. 2025. PMID: 39617268 Review.
-
Protease inhibitor-containing antiretroviral treatment and tuberculosis: can rifabutin fill the breach?Int J Tuberc Lung Dis. 2012 Jan;16(1):6-15. doi: 10.5588/ijtld.10.0626. Epub 2011 Aug 3. Int J Tuberc Lung Dis. 2012. PMID: 21819645 Review.
Cited by
-
Phenotype versus genotype discordant rifampicin susceptibility testing in tuberculosis: implications for a diagnostic accuracy.Microbiol Spectr. 2024 Jan 11;12(1):e0163123. doi: 10.1128/spectrum.01631-23. Epub 2023 Nov 20. Microbiol Spectr. 2024. PMID: 37982632 Free PMC article.
-
Comparison of line probe assay to BACTEC MGIT 960 system for susceptibility testing of first and second-line anti-tuberculosis drugs in a referral laboratory in South Africa.BMC Infect Dis. 2017 Dec 28;17(1):795. doi: 10.1186/s12879-017-2898-3. BMC Infect Dis. 2017. PMID: 29282012 Free PMC article.
-
Insights into the in-vitro Susceptibility and Drug-Drug Interaction Profiles Against Drug-Resistant and Susceptible Mycobacterium tuberculosis Clinical Isolates in Amhara, Ethiopia.Infect Drug Resist. 2024 Jan 10;17:89-107. doi: 10.2147/IDR.S440947. eCollection 2024. Infect Drug Resist. 2024. PMID: 38223563 Free PMC article.
-
Structural Design and Synthesis of Novel Cyclic Peptide Inhibitors Targeting Mycobacterium tuberculosis Transcription.Life (Basel). 2022 Aug 28;12(9):1333. doi: 10.3390/life12091333. Life (Basel). 2022. PMID: 36143370 Free PMC article.
-
Characterization of Genetic Variants Associated with Rifampicin Resistance Level in Mycobacterium tuberculosis Clinical Isolates Collected in Guangzhou Chest Hospital, China.Infect Drug Resist. 2022 Sep 27;15:5655-5666. doi: 10.2147/IDR.S375869. eCollection 2022. Infect Drug Resist. 2022. PMID: 36193294 Free PMC article.
References
-
- Berrada Z. L., Lin S. Y., Rodwell T. C., Nguyen D., Schecter G. F., Pham L., et al. (2016). Rifabutin and rifampin resistance levels and associated rpoB mutations in clinical isolates of Mycobacterium tuberculosis complex. Diagn. Microbiol. Infect. Dis. 85 177–181. 10.1016/j.diagmicrobio.2016.01.019 - DOI - PMC - PubMed
-
- Campbell P. J., Morlock G. P., Sikes R. D., Dalton T. L., Metchock B., Starks A. M., et al. (2011). Molecular detection of mutations associated with first- and second-line drug resistance compared with conventional drug susceptibility testing of Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 55 2032–2041. 10.1128/AAC.01550-10 - DOI - PMC - PubMed
-
- CDC (2013). Managing Drug Interactions in the Treatment of HIV-Related Tuberculosis. Atlanta, GA: Centers for Disease Control and Prevention.
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources